Stock listing

NASDAQ:XFOR X4 Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of X4 Pharmaceuticals, Inc.

Follow X4 Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:XFOR

$3.00 USD +0.02 (+0.7%)

Close on Nov 20, 2026

Past year -18.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.89 – $3.06 USDNov 20, 2026
Volume
1.83M sharesNov 20, 2026
Market cap
$306.3M USDAt the close on Nov 20, 2026 · price × 102.1M shares outstanding
52-week range
$2.43 – $4.83 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.85M USDMedian day 642,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
X4 Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:XFOR · Home$3.00 USD+0.02 (+0.7%)1,825,293$2.93$3.06$2.89$2.98Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:XFOR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.00+0.02+0.7%$2.93$3.06$2.891,825,293
$2.98-0.11-3.6%$3.09$3.268$2.965642,205
$3.09+0.26+9.2%$2.87$3.11$2.811,113,447
$2.83-0.29-9.3%$3.10$3.13$2.82672,340
$3.12-0.05-1.6%$3.20$3.20$2.975501,341
$3.17-0.06-1.9%$3.18$3.20$2.952,163,082
$3.23-0.015-0.5%$3.27$3.36$3.175775,738
$3.245-0.085-2.6%$3.29$3.35$3.22467,510
$3.33+0.15+4.7%$3.24$3.45$3.18891,254
$3.18+0.11+3.6%$3.04$3.205$2.90527,189
$3.07-0.17-5.2%$3.07$3.13$2.895607,556
$3.24+0.07+2.2%$3.30$3.36$3.11536,564
$3.17-0.18-5.4%$3.37$3.42$3.135630,983
$3.350.000.0%$3.40$3.47$3.26521,958
$3.35-0.01-0.3%$3.33$3.41$3.19706,226
$3.36+0.01+0.3%$3.39$3.49$3.05908,046
$3.35+0.10+3.1%$3.24$3.36$3.14534,947
$3.250.000.0%$3.20$3.30$3.051,607,224
$3.25+0.01+0.3%$3.265$3.30$3.14701,646
$3.24+0.04+1.3%$3.16$3.25$3.02536,600
$3.20+0.19+6.3%$2.99$3.28$2.96591,800
$3.01-0.01-0.3%$3.02$3.12$2.875406,900
$3.02+0.27+9.8%$2.79$3.07$2.77593,300
$2.75+0.16+6.2%$2.60$2.82$2.58603,000
$2.59-0.05-1.9%$2.64$2.71$2.52967,600
$2.64+0.19+7.8%$2.48$2.655$2.475549,800
$2.45-0.15-5.8%$2.54$2.55$2.43705,700
$2.60-0.22-7.8%$2.81$2.83$2.59439,500
$2.82-0.09-3.1%$2.89$2.93$2.81404,300
$2.91+0.12+4.3%$2.83$2.965$2.815541,200
$2.79-0.02-0.7%$2.77$2.81$2.70836,500
$2.81+0.04+1.4%$2.74$2.86$2.70435,400
$2.77-0.13-4.5%$2.90$2.90$2.70642,500
$2.90+0.07+2.5%$2.88$2.935$2.73698,100
$2.830.000.0%$2.86$2.86$2.745911,400
$2.83-0.07-2.4%$2.89$2.95$2.82501,500
$2.900.000.0%$2.93$2.935$2.8451,764,600
$2.90-0.115-3.8%$3.01$3.055$2.8951,709,300
$3.015+0.005+0.2%$2.996$3.04$2.81838,300
$3.01+0.01+0.3%$2.98$3.083$2.9651,856,500
$3.00-0.11-3.5%$3.10$3.10$2.955973,600
$3.11-0.32-9.3%$3.41$3.42$3.0352,309,100
$3.43-0.065-1.9%$3.52$3.57$3.40922,400
$3.495-0.085-2.4%$3.58$3.58$3.455444,400
$3.58+0.08+2.3%$3.48$3.635$3.481,543,400
$3.50-0.01-0.3%$3.56$3.585$3.41635,100
$3.51-0.11-3.0%$3.63$3.65$3.355973,300
$3.620.000.0%$3.60$3.64$3.312,081,100
$3.62+0.12+3.4%$3.51$3.711$3.471,017,900
$3.50+0.10+2.9%$3.44$3.55$3.241,252,900
$3.40-0.20-5.6%$3.60$3.675$3.312,570,100
$3.60+0.095+2.7%$3.50$3.67$3.451,402,200
$3.505-0.535-13.2%$4.00$4.125$3.192,322,400
$4.040.000.0%$4.01$4.08$4.00168,200
$4.040.000.0%$4.06$4.069$3.99409,400
$4.04-0.03-0.7%$4.10$4.17$4.015361,000
$4.07+0.03+0.7%$3.97$4.11$3.97203,800
$4.040.000.0%$4.02$4.10$4.00245,900
$4.04-0.19-4.5%$4.22$4.23$4.00356,200
$4.23+0.06+1.4%$4.18$4.39$4.145597,200
$4.17+0.01+0.2%$4.16$4.23$4.075707,100
$4.16+0.11+2.7%$4.05$4.18$3.995390,755
$4.05+0.01+0.2%$4.03$4.095$3.94299,166
$4.04+0.01+0.2%$4.05$4.175$4.0051,219,600
$4.03-0.13-3.1%$4.12$4.22$3.99561,200

Splits

2 splits since 2019 · NASDAQ:XFOR · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
1-for-6Consolidation
Ticker
NASDAQ:XFOR
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All X4 Pharmaceuticals, Inc. news

X4 Pharmaceuticals, Inc. on 6ix

News releases
22 in the last 12 months · 130 in all · newest Nov 4, 2026 · oldest 2019
Calls
19 calls with a replay · 19 with a transcript · latest May 1, 2025
Decks
23 decks · latest Oct 29, 2026

Where X4 Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:XFOR · Home listing · This pageNASDAQUnited StatesUSD
BOATS:XFORBOATSUnited StatesUSD
gettex:48Q0gettexGermanyEUR
Lang & Schwarz:A3E4QRLang & SchwarzGermanyEUR
Frankfurt:48Q0FrankfurtGermanyEUR
LS Exchange:A3E4QRLS ExchangeGermanyEUR

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$193.6M USD
P/E
Loss
EV/sales
19.4×
EV/EBITDA
Negative EBITDA
Price/book
2.2×
Gross margin
138.5%
Operating margin
−803.9%
Net margin
−805.2%
Debt to equity
0.5×
Beta vs S&P 500
1.35

Forecasts

5 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
11.60 USD · Analysts' mean
EPS, year to Dec 2026
-0.64 · 5 analysts
Revenue, year to Dec 2026
17.28M · 5 analysts

Team and board

Officers

OfficerRole
Paula RaganCEO & President
David KirskeChief Financial Officer
John VolponePresident, Chief Operating Officer
Adam CraigExecutive Chair

Board

DirectorRole
Adam CraigExecutive Chair
Françoise de CraeckerBoard Member
Gary L. BridgerBoard Member
Michael WyzgaLead Independent Director
Murray StewartBoard Member

Events

Calls

CallWhenStatus
X4 Pharmaceuticals (NASDAQ:XFOR) Q1 2025 Earnings CallWed, Apr 30, 2025 · 10:30 PM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q4 2024 Earnings CallTue, Mar 25, 2025 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q3 2024 Earnings CallWed, Nov 13, 2024 · 8:00 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q2 2024 Earnings CallThu, Aug 08, 2024 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q1 2024 Earnings CallTue, May 07, 2024 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q4 2023 Earnings CallThu, Mar 21, 2024 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q3 2023 Earnings CallThu, Nov 09, 2023 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q2 2023 Earnings CallThu, Aug 10, 2023 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q1 2023 Earnings CallThu, May 04, 2023 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q4 2022 Earnings CallTue, Mar 21, 2023 · 9:00 AM ETReplay
All 19 calls
CallWhenStatus
X4 Pharmaceuticals (NASDAQ:XFOR) Q3 2022 Earnings CallThu, Nov 03, 2022 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q2 2022 Earnings CallThu, Aug 04, 2022 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q1 2022 Earnings CallThu, May 12, 2022 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q4 2021 Earnings CallThu, Mar 17, 2022 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q3 2021 Earnings CallThu, Nov 04, 2021 · 9:00 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q2 2021 Earnings CallTue, Aug 03, 2021 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q1 2021 Earnings CallThu, May 06, 2021 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q4 2020 Earnings CallThu, Mar 04, 2021 · 8:30 AM ETReplay
X4 Pharmaceuticals (NASDAQ:XFOR) Q3 2020 Earnings CallThu, Oct 22, 2020 · 9:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−5.3%
Q2 2026Aug 6, 2026 · After close+11.3%
Q1 2026May 6, 2026 · Before open+4.3%
Q4 2025Mar 17, 2026+13.8%
Q3 2025Nov 5, 2025 · Before open−10.6%
Q2 2025Aug 8, 2025 · After close−4.7%
Q1 2025May 1, 2025 · Before open−13.0%
Q4 2024Mar 19, 2025 · Before open+1.7%
Q3 2024Nov 13, 2024 · Before open−53.2%
Q2 2024Aug 8, 2024 · Before open+3.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · Before open−9.2%
Q4 2023Mar 21, 2024 · Before open+28.4%
Q3 2023Nov 9, 2023 · Before open+6.6%
Q2 2023Aug 10, 2023 · Before open−36.0%
Q1 2023May 4, 2023 · Before open+4.0%
Q4 2022Mar 21, 2023 · Before open+0.9%
Q3 2022Nov 3, 2022 · Before open−3.6%
Q2 2022Aug 4, 2022 · Before open−1.6%
Q1 2022May 12, 2022 · Before open−0.9%
Q4 2021Mar 17, 2022 · Before open−10.6%

Open Events

Decks

DeckKindSlidesDate
Investor Day (October 2026)Investor day34 slidesOct 29, 2026
Investor Presentation (October 2026)Investor deck20 slidesOctober 2026
Investor Presentation (September 2026)Investor deck20 slidesSep 9, 2026
Investor Presentation (May 2025)Investor deck32 slidesMay 1, 2025
Investor Presentation (January 2025)Investor deck32 slidesJan 13, 2025
Q3 2024 Earnings PresentationEarnings28 slidesNov 13, 2024
Investor Day (June 2024)Investor day31 slidesJun 27, 2024
Investor Presentation (May 2024)Investor deck26 slidesMay 22, 2024
Corporate Update (April 2024)Corporate update26 slidesApr 29, 2024
Technical Presentation (February 2024)Technical15 slidesFebruary 2024
All 23 decks
DeckKindSlidesDate
Investor Day (May 2023)Investor day29 slidesMay 16, 2023
Technical Presentation (May 2023)Technical23 slidesMay 2023
Technical Presentation (May 2023)Technical20 slidesMay 2023
ASH 2022Conference16 slidesDecember 2022
Corporate Update (November 2022)Corporate update19 slidesNov 29, 2022
Q3 2022 Earnings PresentationEarnings18 slidesNov 3, 2022
Technical Presentation (November 2022)Technical11 slidesNovember 2022
Technical Presentation (September 2022)Technical24 slidesSep 27, 2022
Investor Presentation (August 2022)Investor deck25 slidesAug 5, 2022
ASH 2021Conference8 slidesDec 16, 2021
Technical Presentation (September 2019)Technical15 slidesSep 30, 2019
Investor Presentation (April 2019)Investor deck20 slidesApr 1, 2019
Arsanis — Merger or Acquisition (November 2018)Merger or acquisition20 slidesNov 27, 2018

Open Decks

Financings

RaiseDate
Public offering of shares of common stock and pre-funded warrants
Closed: US$155.3M raised · US$2.9 a share · Leerink Partners +2
Dealers: Leerink Partners (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead)
Use of proceeds: Fund pivotal Phase 3 development of mavorixafor in chronic neutropenic disorders, G&A, capital expenditures, working capital and general corporate purposes
Oct 27, 2025
Private placement of shares of common stock and pre-funded warrants
Closed: US$85M raised · US$1.42 a share · Stifel
Dealers: Stifel (lead)
Buyers: Coastlands Capital (led the offering); Bain Capital Life Sciences (existing investor); New Enterprise Associates; BVF Partners LP; Deep Track Capital; Kalehua Capital; Nantahala Capital; Stonepine Capital Management; Trails Edge Capital Partners; Empery Asset Management, LP (existing investor); New Enterprise Associates (NEA) (existing investor)
Use of proceeds: Continued development towards potential additional approval of mavorixafor in chronic neutropenia and commercialization in WHIM
Aug 13, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Arsanis, Inc. Priced at US$10.00 a share on Nov 15, 2017.

Price
US$10.00 a share
Shares offered
4,000,000 shares of common stock
Offering size
US$40 million
Underwriters' option
Up to 600,000 more shares
Underwriters
Citigroup, Cowen, Piper Jaffray · In the order on the cover
Shares delivered
On or about Nov 20, 2017

Steps

StepWhen
Draft sent to the SEC in confidenceAug 10, 2017
Filed publiclyOct 20, 2017
Amended twiceNewest Nov 15, 2017
Shares registered with an exchangeNov 15, 2017
Declared effective by the SECNov 15, 2017
Final prospectus, with the priceNov 17, 2017

Open IPO · From the cover of the final prospectus (424B1) filed Nov 17, 2017

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue6.50M2.60M0003.00M0000
Cost of revenue5.76M797.0K001.89M1.23M672.0K103.0K195.0K300.0K
Gross profit28.9M1.76M-2.00M-1.99M-1.89M3.00M-672.0K-103.0K-195.0K-300.0K
Research and development72.7M81.6M72.0M61.1M50.6M41.9M30.2M20.3M17.1M17.8M
Selling, general and administrative43.5M61.5M32.1M27.0M24.7M20.9M17.6M18.4M8.01M6.51M
Operating income-86.9M-36.4M-107.5M-87.6M-85.1M-59.9M-51.7M-29.1M-22.2M-24.3M
Depreciation and amortization1.28M796.0K419.0K513.0K499.0K351.0K103.0K103.0K71.0K285.0K
EBITDA-85.6M-35.6M-107.1M-87.1M-84.6M-59.5M-51.6M-29.0M-22.2M-24.1M
Interest expense8.88M8.77M5.78M3.99M3.64M2.69M2.15M720.0K490.0K2.52M
Income before tax-79.2M-37.1M-101.1M-93.8M-88.7M-62.0M-52.8M-33.3M-22.0M-23.0M
Income tax41.0K310.0K78.0K28.0K17.0K148.0K001.87M2.62M
Net income-79.2M-37.5M-101.2M-93.9M-88.7M-62.1M-52.8M-33.3M-22.0M-23.0M
Earnings per share, basic-1.87-5.59-17.07-1.52-3.99-3.09-4.63-79.15-54.58-44.79
Earnings per share, diluted-1.87-5.59-17.07-1.52-3.99-3.09-4.63-79.15-54.58-44.79

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents217.0M55.7M99.2M121.7M81.8M78.7M126.2M8.13M26.7M15.2M
Short-term investments35.9M46.4M15.0M0
Receivables573.0K1.07M01.15M747.0K917.0K02.86M1.61M1.34M
Inventory4.48M2.82M0-747.0K355.0K1.25M
Current assets261.6M112.2M122.1M128.7M87.9M83.3M129.3M9.34M79.5M5.72M
Property, plant and equipment182.0K776.0K745.0K1.10M1.51M1.24M403.0K241.0K421.0K37.0K
Goodwill17.4M17.4M17.4M17.4M17.4M27.1M27.1M0
Total assets290.5M146.4M147.3M155.6M117.2M122.9M160.7M9.94M81.3M7.60M
Accounts payable5.70M8.62M8.95M7.78M4.28M3.14M2.09M2.97M1.89M1.65M
Current liabilities25.8M32.9M22.9M22.3M14.0M11.9M9.45M7.91M10.7M12.1M
Long-term debt76.3M75.4M54.6M32.3M33.1M33.2M20.0M8.31M9.92M10.1M
Total debt75.0M75.0M55.0M32.5M32.5M32.5M20.0M10.0M12.2M15.3M
Total liabilities104.2M124.3M96.2M81.5M52.8M50.1M31.5M21.6M22.5M24.3M
Shareholders' equity186.3M22.1M51.1M74.1M64.4M72.8M129.2M-77.1M-44.5M-23.1M
Shares outstanding90.9M5.70M167.4M121.7M28.1M16.3M16.1M351.7K14.3M16.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-85.6M-130.9M-96.5M-77.1M-70.9M-58.8M-48.1M-25.4M-21.3M-21.6M
Capital spending0-326.0K-60.0K-103.0K-615.0K-1.36M-174.0K0-378.0K-73.0K
Free cash flow-85.6M-131.2M-96.6M-77.2M-71.5M-60.2M-48.2M-25.4M-21.7M-21.7M
Cash from investing8.15M67.0M-14.9M-103.0K-615.0K-1.36M27.2M0-378.0K-73.0K
Cash from financing238.6M20.3M88.5M117.2M74.2M12.4M140.7M6.87M33.4M18.1M
Dividends paid-12-13.9M-12.4M-20.0M-45.7M
Share buybacks00-2.00M00-1.13M-197.0K-87.0K
Change in cash161.4M-43.8M-22.8M39.9M2.41M-47.4M119.6M-18.6M11.7M-3.67M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
8-K · Current reportOct 29, 2026Current reportSEC
4 · Change in ownershipOct 19, 2026Insider tradeSEC
8-K · Current reportOct 8, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 7, 2026Big-stake noticeSEC
4 · Change in ownershipOct 5, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeSep 21, 2026Big-stake noticeSEC
8-K · Current reportSep 8, 2026Current reportSEC
8-K · Current reportSep 8, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeJul 30, 2026Big-stake noticeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
4 · Change in ownershipJul 1, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 1, 2026Insider tradeSEC
8-K · Current reportJul 1, 2026Management or board changeSEC
EFFECT · Notice that a registration is effectiveMay 18, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K/A · Current report, amendedMay 13, 2026Management or board changeSEC
4 · Change in ownershipMay 13, 2026Insider tradeSEC
144 · Notice of proposed saleMay 12, 2026Other filingsSEC
8-K · Current reportMay 12, 2026Management or board changeSEC
CORRESP · Letter to the SECMay 12, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 11, 2026Other filingsSEC
S-3 · Registration statementMay 6, 2026Offer documentSEC
10-Q · Quarterly reportMay 6, 2026Quarterly reportSEC
ARS · Annual report to shareholdersMar 20, 2026Annual reportSEC
DEFA14A · Additional proxy materialMar 20, 2026Meeting noticeSEC
DEF 14A · Proxy statementMar 20, 2026Meeting noticeSEC
S-8 · Registration statement for employee plansMar 17, 2026Offer documentSEC
10-K · Annual reportMar 17, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 6, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 12, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 15, 2026Big-stake noticeSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2025Quarterly reportSEC
8-K · Current reportNov 5, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 3, 2025Big-stake noticeSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 29, 2025Big-stake noticeSEC
4 · Change in ownershipOct 27, 2025Insider tradeSEC
8-K · Current reportOct 24, 2025Material contractSEC
424B5 · ProspectusOct 24, 2025Offer documentSEC
424B5 · ProspectusOct 23, 2025Offer documentSEC
SCHEDULE 13G · Big-stake noticeOct 21, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 3, 2025Big-stake noticeSEC
424B3 · ProspectusSep 18, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 18, 2025Other filingsSEC
8-K · Current reportSep 17, 2025Management or board changeSEC
CORRESP · Letter to the SECSep 15, 2025Other filingsSEC
SCHEDULE 13G · Big-stake noticeSep 15, 2025Big-stake noticeSEC
UPLOAD · Letter from the SECSep 15, 2025Other filingsSEC
S-3 · Registration statementSep 10, 2025Offer documentSEC
S-8 · Registration statement for employee plansSep 10, 2025Offer documentSEC
DAug 25, 2025Other filingsSEC
8-K · Current reportAug 25, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeAug 20, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 19, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 18, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeAug 18, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 15, 2025Big-stake noticeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
4 · Change in ownershipAug 14, 2025Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeAug 13, 2025Big-stake noticeSEC
8-K · Current reportAug 13, 2025Material contractSEC
8-K · Current reportAug 12, 2025Material contractSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 18, 2025Big-stake noticeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
8-K · Current reportJun 23, 2025Material contractSEC
424B5 · ProspectusJun 23, 2025Offer documentSEC
8-K · Current reportJun 11, 2025Meeting outcomeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
4 · Change in ownershipJun 10, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 3, 2025Insider tradeSEC
4/A · Change in ownership, amendedJun 3, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
10-Q · Quarterly reportMay 1, 2025Quarterly reportSEC
8-K · Current reportMay 1, 2025ResultsSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
8-K · Current reportApr 24, 2025Current reportSEC
8-K · Current reportApr 18, 2025Meeting outcomeSEC
S-8 · Registration statement for employee plansMar 26, 2025Offer documentSEC
10-K · Annual reportMar 25, 2025Annual reportSEC
8-K · Current reportMar 25, 2025ResultsSEC
DEF 14A · Proxy statementMar 24, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementMar 14, 2025Meeting noticeSEC
8-K · Current reportMar 3, 2025Current reportSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
8-K · Current reportFeb 6, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 31, 2025Big-stake noticeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
4 · Change in ownershipJan 27, 2025Insider tradeSEC
144 · Notice of proposed saleJan 24, 2025Other filingsSEC
144 · Notice of proposed saleJan 24, 2025Other filingsSEC
144 · Notice of proposed saleJan 24, 2025Other filingsSEC
144 · Notice of proposed saleJan 24, 2025Other filingsSEC
144 · Notice of proposed saleJan 24, 2025Other filingsSEC
144 · Notice of proposed saleJan 24, 2025Other filingsSEC
S-8 · Registration statement for employee plansJan 16, 2025Offer documentSEC
8-K · Current reportJan 13, 2025Material contractSEC
UPLOAD · Letter from the SECJan 7, 2025Other filingsSEC
CORRESP · Letter to the SECDec 23, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 13, 2024Other filingsSEC
4 · Change in ownershipNov 19, 2024Insider tradeSEC
144 · Notice of proposed saleNov 15, 2024Other filingsSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
8-K · Current reportNov 13, 2024Current reportSEC
8-K · Current reportNov 13, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
4 · Change in ownershipOct 16, 2024Insider tradeSEC
144 · Notice of proposed saleOct 15, 2024Other filingsSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
4 · Change in ownershipOct 8, 2024Insider tradeSEC
144 · Notice of proposed saleOct 7, 2024Other filingsSEC
144 · Notice of proposed saleOct 7, 2024Other filingsSEC
144 · Notice of proposed saleOct 7, 2024Other filingsSEC
144 · Notice of proposed saleOct 7, 2024Other filingsSEC
144 · Notice of proposed saleOct 7, 2024Other filingsSEC
S-8 · Registration statement for employee plansOct 4, 2024Offer documentSEC
4 · Change in ownershipSep 11, 2024Insider tradeSEC
144 · Notice of proposed saleSep 9, 2024Other filingsSEC
8-K · Current reportAug 16, 2024Current reportSEC
8-K · Current reportAug 9, 2024Current reportSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
8-K · Current reportJul 19, 2024Current reportSEC
8-K · Current reportJun 27, 2024Current reportSEC
8-K · Current reportJun 11, 2024Meeting outcomeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC
8-K · Current reportMay 22, 2024Current reportSEC
8-K · Current reportMay 9, 2024Acquisition or disposalSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
8-K · Current reportApr 29, 2024Current reportSEC
8-K · Current reportApr 29, 2024Current reportSEC
8-K · Current reportApr 5, 2024Current reportSEC
8-K · Current reportApr 1, 2024Current reportSEC
10-K · Annual reportMar 21, 2024Annual reportSEC
8-K · Current reportMar 21, 2024ResultsSEC
4 · Change in ownershipMar 11, 2024Insider tradeSEC
4 · Change in ownershipMar 11, 2024Insider tradeSEC
4 · Change in ownershipMar 11, 2024Insider tradeSEC
4 · Change in ownershipMar 11, 2024Insider tradeSEC
144 · Notice of proposed saleMar 11, 2024Other filingsSEC

This page holds 200 of 821 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from X4 Pharmaceuticals, Inc.’s releases · as of Nov 2, 2026

Common shares
102,113,554
Fully diluted
102,113,554

Fully diluted

LineSharesAs of
Common shares102,113,554Nov 2, 2026

Share count over time

CountShares
Nov 2, 2026102,113,554

Open Cap table

Shareholders

Institutions

HolderSharesValueChange vs Jun 30Filed
Morgan Stanley11MUS$31.9M+1.53MNov 13, 2026
Empery Asset Management, LP9.73MUS$28.2M+2.79MNov 16, 2026
Bain Capital Life Sciences Investors, LLC7.97MUS$23.1MNo changeNov 16, 2026
Venrock Adviser, LLC7.64MUS$22.2M+5.71MNov 16, 2026
Saturn V Capital Management LP7.37MUS$21.4M+393KNov 16, 2026
Perceptive Advisors LLC7.35MUS$21.3M−583KNov 16, 2026
BlackRock5.85MUS$17M+300KNov 13, 2026
Fidelity5.49MUS$15.9M−2.83MNov 10, 2026
Vanguard4.68MUS$13.6M−186KNov 13, 2026
Deep Track Capital, LP4.5MUS$13.1M−1.38MNov 16, 2026
Show 50 holders
HolderSharesValueChange vs Jun 30Filed
Kalehua Capital Management LLC3.72MUS$10.8M−3.72MNov 13, 2026
Rosalind Advisors, Inc.3.21MUS$9.32MNo changeNov 16, 2026
Trails Edge Capital Partners, LP2.57MUS$7.46MNo changeNov 16, 2026
Nantahala Capital Management, LLC2.45MUS$7.1M−2.45MNov 13, 2026
Blackstone Inc.2.43MUS$7.04M−255KNov 16, 2026
Braidwell LP2.34MUS$6.8M−578KNov 16, 2026
Goldman Sachs2.34MUS$6.77M+1.42MNov 16, 2026
Affinity Asset Advisors, LLC2.06MUS$5.98M+1.92MNov 13, 2026
Geode Capital2.05MUS$5.94M−50,766Nov 6, 2026
State Street1.73MUS$5.02M+434KNov 12, 2026
Bvf Inc1.58MUS$4.57M−657KNov 16, 2026
Samsara Biocapital, LLC1.35MUS$3.91M−47,864Nov 16, 2026
Woodline Partners LP1MUS$2.9MNo changeNov 16, 2026
Northern Trust628KUS$1.82M−25,105Nov 16, 2026
Verdad Advisers, LP323KUS$937K−28,927Nov 16, 2026
Wellington289KUS$839K+237KNov 16, 2026
Schwab263KUS$764K+18Nov 16, 2026
Integral Health Asset Management, LLC250KUS$725KNewNov 16, 2026
Russell Investments Group, Ltd.213KUS$618K+206KNov 6, 2026
BNY205KUS$594K+8,651Nov 5, 2026
Citadel150KUS$436KNewNov 16, 2026
Stonepine Capital Management, LLC150KUS$435K−74,989Nov 13, 2026
Alps Advisors Inc130KUS$378K+34,698Nov 2, 2026
Susquehanna120KUS$347K+18,474Nov 16, 2026
Invesco117KUS$340K+20,458Nov 12, 2026
Renaissance Technologies116KUS$335K+97,424Nov 12, 2026
American Century114KUS$330K+38,941Nov 20, 2026
Nuveen111KUS$322K+3,668Nov 10, 2026
Prudential Financial Inc110KUS$318K+97,205Nov 16, 2026
XTX Topco Ltd101KUS$292KNewNov 16, 2026
Rhumbline Advisers94,984US$275K−97Nov 10, 2026
Point72 Asset Management, L.P.93,565US$271K+52,493Nov 16, 2026
Squarepoint Ops LLC83,488US$242K+16,410Nov 9, 2026
Bank of America70,237US$204K+23,376Nov 16, 2026
EntryPoint Capital, LLC70,147US$203KNewNov 13, 2026
DWS68,976US$200K−9,909Nov 6, 2026
Algert Global LLC67,553US$196KNewNov 17, 2026
T. Rowe Price66,379US$193KNo changeNov 16, 2026
UBS49,642US$144K−8,401Nov 16, 2026
Palumbo Wealth Management LLC48,373US$140K−18,743Nov 12, 2026

This page holds 50 of 91 holders. Open Shareholders

Funds

HolderSharesValueChangeAs of
Fidelity Small Cap Growth Fund3.39MUS$13.5MNo changeJul 31, 2026
Vanguard Total Stock Market Index Fund2.6MUS$12.1M+114KJun 30, 2026
Inception Portfolio2.31MUS$10.8M−24,888Jun 30, 2026
iShares Russell 2000 ETF1.91MUS$8.91MNewJun 30, 2026
EQ/Morgan Stanley Small Cap Growth Portfolio1.82MUS$8.49MNo changeJun 30, 2026
Fidelity Small Cap Growth K6 Fund1.69MUS$6.73MNo changeJul 31, 2026
Select Biotechnology Portfolio1.43MUS$6.16M−257KMay 31, 2026
Fidelity Advisor Biotechnology Fund1.34MUS$5.34MNo changeJul 31, 2026
Vanguard Extended Market Index Fund1.03MUS$4.82M+112KJun 30, 2026
Fidelity Small Cap Index Fund885KUS$3.52MNewJul 31, 2026
Show 50 holders
HolderSharesValueChangeAs of
iShares Russell 2000 Value ETF758KUS$3.54MNewJun 30, 2026
Fidelity Small Cap Stock Fund505KUS$2.01MNewJul 31, 2026
Fidelity Extended Market Index Fund423KUS$1.82M+17,676May 31, 2026
iShares Micro-Cap ETF271KUS$1.27MNewJun 30, 2026
Schwab Small-Cap Index Fund197KUS$782KNewJul 31, 2026
Fidelity Total Market Index Fund167KUS$722KNo changeMay 31, 2026
Master Small Cap Index Series151KUS$706KNewJun 30, 2026
Fidelity Series Total Market Index Fund124KUS$536K−15,380May 31, 2026
Fidelity Small Cap Value Index Fund113KUS$527KNewJun 30, 2026
Nuveen Small Cap Blend Index Fund107KUS$427KNewJul 31, 2026
EQ/2000 Managed Volatility Portfolio86,641US$405KNewJun 30, 2026
U.S. Small Cap Equity Fund79,833US$318KNewJul 31, 2026
Schwab Total Stock Market Index Fund66,731US$266KNo changeJul 31, 2026
LVIP State Street Small-Cap Index Fund59,100US$276KNewJun 30, 2026
Fidelity Nasdaq Composite Index Fund56,741US$245KNo changeMay 31, 2026
Avantis U.S. Small Cap Equity ETF46,744US$201KNewMay 31, 2026
Vanguard Balanced Index Fund42,532US$199K−6,250Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund42,268US$197KNo changeJun 30, 2026
Small Cap Index Fund41,980US$196KNewJun 30, 2026
Global X Russell 2000 ETF38,483US$153KNewJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF30,166US$120K+10,210Jul 31, 2026
State Street Small/Mid Cap Equity Index Portfolio29,000US$135KNewJun 30, 2026
MetLife Russell 2000 Index Portfolio27,197US$127KNewJun 30, 2026
Small-Cap Index Portfolio23,222US$108KNewJun 30, 2026
ATM Small Cap Managed Volatility Portfolio22,814US$107KNewJun 30, 2026
1290 VT Micro Cap Portfolio18,231US$85,139NewJun 30, 2026
NVIT Small Cap Index Fund17,857US$83,392NewJun 30, 2026
Small Cap Index Trust16,839US$78,638NewJun 30, 2026
iShares Russell Small/Mid-Cap Index Fund14,446US$57,495NewJul 31, 2026
DWS Small Cap Index VIP12,703US$59,323NewJun 30, 2026
1290 VT Small Cap Value Portfolio12,524US$58,487NewJun 30, 2026
T. Rowe Price Small-Cap Index Fund12,192US$56,937NewJun 30, 2026
iShares Total U.S. Stock Market Index Fund11,344US$45,149NewJul 31, 2026
BlackRock Small Cap Index V.I. Fund10,917US$50,982NewJun 30, 2026
Voya RussellTM Small Cap Index Portfolio10,068US$47,018NewJun 30, 2026
SA Small Cap Index Portfolio9,468US$37,683NewJul 31, 2026
Victory Extended Market Index Fund8,775US$34,925+1,055Jul 31, 2026
Fidelity Small Cap Stock K6 Fund8,308US$33,066NewJul 31, 2026
CVT Russell 2000 Small Cap Index Portfolio7,338US$34,268NewJun 30, 2026
Nationwide Small Cap Index Fund7,216US$28,720NewJul 31, 2026

This page holds 50 of 74 holders. Open Shareholders

Insider trades

InsiderTradeSharesPriceValueDate
Craig Adam R
Director, Officer: Executive Chairman
Buy4,600USD 2.58US$11,884Oct 16, 2026
Kirske David
Officer: Chief Financial Officer
Sale11,767USD 2.86US$33,658Oct 1, 2026
Craig Adam R
Director, Officer: Executive Chairman
Sale47,436USD 4.44US$211KAug 12, 2026
Volpone John
Officer: President
Sale24,576USD 4.44US$109KAug 12, 2026
Kirske David
Officer: Chief Financial Officer
Sale8,543USD 4.26US$36,393Jun 30, 2026
Kirske David
Officer: Chief Financial Officer
Sale16,961USD 4.29US$72,763May 12, 2026

Big stakes

HolderStakeSharesDate
Morgan Stanley10.20%8.88MFeb 28, 2026
Coastlands Capital LP9.99%10.7MSep 30, 2026
Empery Asset Management, LP9.99%9.04MDec 31, 2025
Perceptive Advisors LLC8.10%8.09MJun 30, 2026
Venrock Healthcare Capital Partners III, L.P.7.60%7.64MSep 30, 2026
BCLS II Equity Opportunities, LP7.43%7.05MDec 31, 2025
Saturn V Capital Management LP7.36%6.43MOct 24, 2025
Deep Track Capital, LP6.58%6.66MSep 30, 2026
Growth Equity Opportunities 18 VGE, LLC6.20%5.06MOct 27, 2025
BlackRock, Inc.5.90%5.53MJun 30, 2026
All 11 stakes
HolderStakeSharesDate
Trails Edge Capital Partners, LP5.80%5.23MDec 31, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carl Gordon
Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); ArriVent BioPharma, Inc. (Director · Jan 25, 2024 – Jan 30, 2024 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Adicet Bio, Inc. (Director · Sep 15, 2020 – Aug 21, 2024 · Past); ORIC Pharmaceuticals, Inc. (Director · Apr 23, 2020 – Jun 16, 2021 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past)
Director · Nov 15, 2017 – Jun 5, 2018 · Past
Michael Wyzga
Other companies: Tvardi Therapeutics, Inc. (Board Member · Since at least Apr 15, 2025); Mereo BioPharma Group plc (Chairman of the Board · Since at least Jan 1, 2024); Kineta Inc. (See Remarks · Aug 16, 2021 – Dec 2, 2022 · Past); Invivyd, Inc. (Director · Aug 5, 2021 – May 23, 2023 · Past); LogicBio Therapeutics Inc (Director · Oct 18, 2018 – Nov 16, 2022 · Past); EXACT Sciences Corporation (Director · Feb 9, 2015 – Feb 26, 2021 · Past); Akebia Therapeutics, Inc. (Director · Mar 19, 2014 – Jun 14, 2018 · Past); OncoMed Pharmaceuticals Inc (Director · Oct 14, 2013 – Jun 22, 2018 · Past); Idenix Pharmaceuticals Inc (Director · Mar 1, 2012 – Aug 5, 2014 · Past); Radius Health, Inc. (Chief Executive Officer, Director · Dec 5, 2011 – Dec 15, 2011 · Past); Genzyme Corp (Executive VP and CFO · May 25, 2006 – Apr 4, 2011 · Past)
Director · Since at least Mar 13, 2019
Terrance McGuire
Other companies: Tectonic Therapeutic, Inc. (Director · Since at least Jun 20, 2024); Invivyd, Inc. (Director · Since at least Aug 5, 2021); Seer, Inc. (Director · Since at least Dec 3, 2020); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Nov 30, 2023 · Past); Alector, Inc. (Director · Feb 6, 2019 – Sep 11, 2023 · Past); Pulmatrix, Inc. (Director · Jun 15, 2015 – May 16, 2019 · Past); Trevena, Inc. (Director · Jan 30, 2014 – May 14, 2014 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Mar 2, 2017 · Past); Ironwood Pharmaceuticals, Inc. (Director · Jun 3, 2013 – Apr 1, 2019 · Past)
Director · Nov 15, 2017 – Jun 5, 2018 · Past
Alison Frances Lawton
Other companies: ProQR Therapeutics N.V. (Director · Since at least Mar 18, 2026); Dianthus Therapeutics, Inc. (Director · Since at least Dec 22, 2020); Spyre Therapeutics, Inc. (Director · Dec 15, 2020 – Jun 22, 2023 · Past); Kaleido Biosciences, Inc. (See Remarks, Director · Feb 27, 2019 – Apr 15, 2020 · Past); CoLucid Pharmaceuticals Inc (Director · Mar 11, 2016 – Mar 1, 2017 · Past); Tempest Therapeutics, Inc. (Chief Operating Officer · Jan 21, 2013 – Jun 7, 2013 · Past); Verastem, Inc. (Director · Nov 26, 2012 – Jun 21, 2019 · Past); Cubist Pharmaceuticals Inc (Director · Feb 15, 2012 – Jan 21, 2015 · Past)
Director · Oct 5, 2020 – Jun 10, 2024 · Past
Amy Schulman
Other companies: Elevance Health, Inc. (Director · Since at least Dec 10, 2025); Fractyl Health, Inc. (Director · Since at least Feb 1, 2024); Alnylam Pharmaceuticals, Inc. (Director · Since at least Jun 20, 2018); Hudson Executive Investment Corp II (Director · Jan 25, 2021 – Apr 13, 2021 · Past); Cyclerion Therapeutics, Inc. (Director · Apr 1, 2019 – Jun 16, 2020 · Past); Ironwood Pharmaceuticals, Inc. (Director · May 31, 2018 – Apr 1, 2019 · Past); Blue Buffalo Pet Products Inc (Director · Apr 24, 2018 – Apr 24, 2018 · Past)
Director · Nov 15, 2017 – Jun 5, 2018 · Past
Isaac Blech
Other companies: Aridis Pharmaceuticals Inc. (Director · Aug 13, 2018 – Aug 13, 2018 · Past); InspireMD Inc. (Director · Jan 22, 2016 – Dec 7, 2016 · Past); Avalo Therapeutics, Inc. (Director · Oct 14, 2015 – Dec 31, 2018 · Past); PDS Biotechnology Corporation (Director · Sep 30, 2015 – Mar 15, 2019 · Past); SpendSmart Networks Inc (Director · Aug 1, 2014 – Jul 19, 2016 · Past); CervoMed Inc. (Director · Jul 24, 2014 – Aug 31, 2016 · Past); Aevi Genomic Medicine LLC (Director · Nov 11, 2013 – Apr 15, 2016 · Past)
Director · Mar 13, 2019 – Mar 13, 2019 · Past
David McGirr
Other companies: Rhythm Pharmaceuticals, Inc. (Director · Since at least Oct 4, 2017); Insmed Incorporated (Director · Since at least Oct 30, 2013); Roka Bioscience Inc (Director · Jul 16, 2014 – Jun 28, 2017 · Past); Relypsa Inc (Director · Nov 14, 2013 – Sep 1, 2016 · Past); Cubist Pharmaceuticals Inc (SVP & Chief Financial Officer · Mar 31, 2010 – Feb 15, 2013 · Past)
Director · Since at least Nov 15, 2017
Michael Jay Ross
Other companies: Xilio Therapeutics, Inc. (Director · Oct 21, 2021 – Jun 15, 2022 · Past); Sutro Biopharma, Inc. (Director · Sep 26, 2018 – Sep 27, 2018 · Past); Deciphera Pharmaceuticals LLC (Director · Sep 27, 2017 – Jun 11, 2019 · Past); Astria Therapeutics Inc (Director · Jun 24, 2015 – Jun 7, 2018 · Past); IVERIC bio Inc (Director · Sep 24, 2013 – May 23, 2018 · Past)
Director · Nov 15, 2017 – Jun 5, 2018 · Past
Keith Woods
Other companies: Neurogene Inc. (Director · Since at least Jun 12, 2025); Scholar Rock Holding Corporation (Chief Operating Officer · Since at least Apr 27, 2025); TScan Therapeutics, Inc. (Director · Since at least Dec 6, 2023); Rocket Pharmaceuticals, Inc. (Director · Dec 7, 2023 – Jun 13, 2024 · Past)
Director · Since at least Oct 16, 2023
Murray Stewart
Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Mar 17, 2025); Amarin Corporation plc (Director · Jan 9, 2023 – Jan 9, 2023 · Past); Rhythm Pharmaceuticals, Inc. (Chief Medical Officer · Oct 15, 2018 – Feb 11, 2021 · Past); Novelion Therapeutics Inc (Executive Vice President, R&D · Nov 27, 2017 – Feb 12, 2018 · Past)
Board Member · Since at least Mar 29, 2019
All 35 people
PersonSeat
Gary L. Bridger
Other companies: Xenon Pharmaceuticals Inc. (EVP, Research & Development · Nov 4, 2014 – Nov 21, 2014 · Past); Alder BioPharmaceuticals Inc (Director · May 7, 2014 – Oct 31, 2015 · Past); Neurogene Inc. (Director · Mar 6, 2014 – May 7, 2018 · Past)
Board Member · Since at least Mar 13, 2019
Michael Gray
Other companies: Upstream Bio, Inc. (CFO and COO · Since at least Oct 10, 2024); POINT Biopharma Global Inc (Director · Jul 7, 2020 – Jul 7, 2020 · Past); Enliven Therapeutics, Inc. (CFO & COO · Mar 11, 2020 – Feb 22, 2023 · Past)
President, CEO and CFO, Director · Nov 15, 2017 – Nov 27, 2018 · Past
William D Clark
Other companies: Aldeyra Therapeutics, Inc. (Director · Since at least Apr 17, 2025); iBio, Inc. (Director · Since at least Aug 23, 2021); Vanda Pharmaceuticals Inc. (Sr. VP, Chief Business Officer · Apr 12, 2006 – Feb 19, 2010 · Past)
Director · Nov 15, 2017 – Jun 5, 2018 · Past
Adam Craig
Other companies: CTi Biopharma Corp (President and CEO, Director · Mar 20, 2017 – Jun 26, 2023 · Past); Sunesis Pharmaceuticals Inc (EVP, Development & CMO · Feb 27, 2012 – Feb 27, 2015 · Past)
Executive Chair · Since at least Aug 12, 2025
Christophe Arbet-Engels
Other companies: Altimmune, Inc. (Chief Medical Officer · Since at least Oct 1, 2025); Tempest Therapeutics, Inc. (Chief Medical Officer · Feb 10, 2020 – May 25, 2020 · Past)
Chief Medical Officer · Aug 16, 2023 – Nov 4, 2026 · Past
Lynne E Kelley
Other companies: Ocugen, Inc. (Chief Medical Officer · Jul 31, 2018 – Oct 1, 2018 · Past); Senseonics Holdings, Inc. (Chief Medical Officer · Mar 17, 2016 – Feb 2, 2018 · Past)
See Remarks · Apr 24, 2019 – Apr 24, 2019 · Past
René Russo
Other companies: Xilio Therapeutics, Inc. (President and Chief Executive Officer · Since at least Oct 21, 2021); Invivyd, Inc. (Director · Aug 5, 2021 – Aug 5, 2021 · Past)
Director · Jun 17, 2019 – Jun 2, 2021 · Past
Tillman U Gerngross
Other companies: Invivyd, Inc. (Chief Executive Officer, Director · Aug 5, 2021 – Jan 30, 2022 · Past); Alector, Inc. (Director · Feb 6, 2019 – Jun 14, 2023 · Past)
Director · Nov 15, 2017 – Jun 5, 2018 · Past
David Kirske
Other companies: CTi Biopharma Corp (EVP, Chief Financial Officer · Jul 1, 2020 – Jun 26, 2023 · Past)
Chief Financial Officer · Since at least Aug 12, 2025
Derek Meisner
Other companies: Acumen Pharmaceuticals, Inc. (Chief Legal Officer & Corp Sec · Since at least Sep 6, 2022)
Chief Legal Officer · Nov 4, 2019 – Aug 17, 2022 · Past
Diego Cadavid
Other companies: Fulcrum Therapeutics, Inc. (SVP Clinical Development · Jul 17, 2019 – Jul 1, 2020 · Past)
Chief Medical Officer · Dec 14, 2020 – Mar 1, 2022 · Past
Mark Baldry
Other companies: Wave Life Sciences Ltd. (Chief Commerical Officer · Aug 5, 2019 – Aug 5, 2019 · Past)
Chief Commercial Officer · Nov 3, 2022 – May 16, 2025 · Past
Paula Ragan
Other companies: CAMP4 Therapeutics Corporation (Director · Since at least Oct 10, 2024)
CEO & President · Since at least Mar 13, 2019
William Aliski
Other companies: Ultragenyx Pharmaceutical Inc. (Director · Jan 30, 2014 – Jun 24, 2021 · Past)
Director · Sep 18, 2019 – Jun 10, 2024 · Past
Adam MostafaChief Financial Officer · Mar 13, 2019 – Nov 4, 2026 · Past
Anthony Chris StevensChief Medical Officer · Nov 15, 2017 – Mar 7, 2018 · Past
Arthur TaverasChief Scientific Officer · Nov 2, 2020 – Oct 4, 2024 · Past
Claudio NessiDirector · Nov 15, 2017 – Jun 5, 2018 · Past
David MantusChief Development Officer · Nov 15, 2017 – Mar 7, 2018 · Past
Eszter NagyChief Scientific Officer · Nov 15, 2017 – Mar 7, 2018 · Past
Françoise de CraeckerBoard Member · Since at least Oct 14, 2021
John VolponePresident, Chief Operating Officer · Since at least Aug 12, 2025
Mary DiBiaseChief Operating Officer · Sep 8, 2021 – Feb 12, 2025 · Past
Natasha Fay ThorenChief Legal Officer · May 20, 2025 – May 20, 2025 · Past
Renato SkerljChief Scientific Officer · Jun 10, 2020 – Sep 9, 2020 · Past

Open People

Log in to ask 6ix AI your own questions about X4 Pharmaceuticals, Inc.